Filtered By:
Cancer: Cancer
Drug: Avastin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1461 results found since Jan 2013.
Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength
CONCLUSIONS: Deuterium MRI at 1.5T proved feasibility to track 2H distribution throughout mouse tissues during D2O administration and revealed a higher 2H accumulation in the tumor xenografts. This research demonstrated a promising successful method for preliminary assessment of radiotherapy and chemotherapy of cancer.PMID:37732903 | DOI:10.1158/1078-0432.CCR-23-1635
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Hirofumi Asano Abdelazim Elsayed Elhelaly Fuminori Hyodo Ryota Iwasaki Yoshifumi Noda Hiroki Kato Koki Ichihashi Hiroyuki Tomita Masaharu Murata Takashi Mori Masayuki Matsuo Source Type: research
Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis
ConclusionTAS-102, fruquintinib, TAS-102 plus bevacizumab, the regorafenib standard dose regimen (regorafenib), and the regorafenib dose-escalation regimen (regorafenib 80+) all demonstrated improved OS and PFS compared to BSC in mCRC patients. However, TAS-102 plus bevacizumab may be the optimal choice for third-line treatment in mCRC patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php, CRD42023434929.
Source: Frontiers in Oncology - September 21, 2023 Category: Cancer & Oncology Source Type: research
EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade
Cancer Immunol Res. 2023 Sep 20. doi: 10.1158/2326-6066.CIR-23-0171. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination of anti-angiogenesis agents and ICB has demonstrated efficacy in several cancers. To improve the mechanistic understanding of synergies with these treatment modalities, we performed serologic screens of human protein array using sera from long-term responding patients treated with ipilimumab and bevacizumab. We discovered a high-titer an...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Saba Tabasum Dinesh Thapa Anita Giobbie-Hurder Jason L Weirather Marco Campisi Pieter J Schol Xiaoyu Li Jingjing Li Charles H Yoon Michael P Manos David A Barbie F Stephen Hodi Source Type: research
Ovarian cancer in the older patient: where are we now? What to do next?
Ther Adv Med Oncol. 2023 Sep 16;15:17588359231192397. doi: 10.1177/17588359231192397. eCollection 2023.ABSTRACTIn recent years, major advances have been made toward the individualization of epithelial ovarian cancer care, leading to an overall improvement of patient outcomes. However, real-life data indicate that the oldest populations do not benefit from this, due to aspects related to cancer (more aggressive histopathological features), treatment (i.e. frequently suboptimal), and the host (increased toxicities in patients with lower physiological reserve). A specific risk-benefit perspective should therefore be taken whe...
Source: Adv Data - September 19, 2023 Category: Epidemiology Authors: Fr édérique Rousseau Florence Ranchon Christophe Bardin Naoual Bakrin Vincent Lavou é Leila Bengrine-Lefevre Claire Falandry Source Type: research
Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
CONCLUSIONS: Compared with Atez/Bev treatment, TACE-Atez/Bev showed better OS, PFS, and ORR for Chinese patients with advanced HCC, with an acceptable safety profile.PMID:37718456 | DOI:10.1186/s12885-023-11389-x
Source: Cancer Control - September 17, 2023 Category: Cancer & Oncology Authors: Fei Cao Changsheng Shi Guofu Zhang Jun Luo Jiaping Zheng Weiyuan Hao Source Type: research
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival
CONCLUSIONS: We validate a three-tier CRS for assessment of pathologic response to NACT in OC and demonstrate its prognostic independence of BRCA status or neoadjuvant bevacizumab use. Improving pR rates may be a useful goal of NACT in OC with the expectation of improved survival. The CRS may be a useful endpoint in clinical trials in OC.PMID:37716223 | DOI:10.1016/j.ygyno.2023.09.002
Source: Gynecologic Oncology - September 16, 2023 Category: Cancer & Oncology Authors: Leah A Marsh Teresa H Kim Mingyan Zhang Kari Kubalanza Charisse Liz Treece Dana Chase Sanaz Memarzadeh Ritu Salani Beth Karlan Jianyu Rao Gottfried E Konecny Source Type: research
LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
CONCLUSIONS: Novel LAPS score may help to facilitate individualized treatment of advanced EGFR-mutated NSCLC receiving EGFR-TKI with or without bevacizumab.PMID:37713583 | DOI:10.1080/07853890.2023.2257227
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Yahua Wu Bin Du Chengliu Lv Xiaohui Ji Jinhuo Lai Source Type: research
Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
J Clin Oncol. 2023 Sep 12:JCO2301858. doi: 10.1200/JCO.23.01858. Online ahead of print.NO ABSTRACTPMID:37699171 | DOI:10.1200/JCO.23.01858
Source: Clinical Colorectal Cancer - September 12, 2023 Category: Cancer & Oncology Source Type: research
Recurrent Glioblastoma: A Review of the Treatment Options
Cancers (Basel). 2023 Aug 26;15(17):4279. doi: 10.3390/cancers15174279.ABSTRACTGlioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been c...
Source: Hand Surgery - September 9, 2023 Category: Surgery Authors: Maria Angeles Vaz-Salgado Mar ía Villamayor V íctor Albarrán V íctor Alía Pilar Sotoca Jes ús Chamorro Diana Rosero Ana M Barrill Mercedes Mart ín Eva Fernandez Jos é Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley Source Type: research
